High resolution mapping of OCA2 intragenic rearrangements and identification of a founder effect associated with a deletion in Polish albino patients

Hum Genet. 2011 Feb;129(2):199-208. doi: 10.1007/s00439-010-0913-5. Epub 2010 Nov 18.

Abstract

Oculocutaneous albinism type 2 (OCA2) represents about 30% of OCA worldwide. Using quantitative multiplex fluorescent PCR and very high-resolution array-CGH focussed on the OCA2 gene and surrounding regions in 15q12, we identified new rearrangements. Deletion 1, encompassing exons 3-20, was present in three patients (including one in the homozygous state), and Deletion 2 (exons 1-20) was found in one patient (heterozygous state). The duplication (exons 3-20) was found in one patient in the homozygous state. Using 14 microsatellite markers we determined haplotypes associated with these rearrangements. Deletion 1 was associated with the same haplotype in three patients who were all of Polish origin, which is strongly in favour of a founder effect. Deletion 2 was associated with a distinct haplotype. The homozygous duplication was inherited from the two unrelated parents of the patients on two different haplotypes. Analysis of the sequences around the breakpoints of these rearrangements showed that all occurred within complex arrays of repetitive sequences. The combined use of very high-resolution array-CGH and of microsatellites (including new intragenic ones described here) constitutes a powerful approach for the precise characterization of OCA2 rearrangements, which have been found in more than 20% of OCA2 patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Albinism, Oculocutaneous / ethnology
  • Albinism, Oculocutaneous / genetics
  • Founder Effect
  • Gene Deletion*
  • Haplotypes
  • Humans
  • Membrane Transport Proteins / genetics*
  • Microsatellite Repeats
  • Oligonucleotide Array Sequence Analysis / methods
  • White People / genetics

Substances

  • Membrane Transport Proteins
  • OCA2 protein, human

Supplementary concepts

  • Oculocutaneous albinism type 2